L
Lipum
Biotech & Life Sciences · Umeå kommun, Sweden · Founded 2010 · IPO 2021
Develops a biological drug for treatment of chronic inflammatory diseases MoreLess
Lipum AB, headquartered in Umeå, Sweden, is an innovative biotech startup focused on developing groundbreaking treatments for chronic inflammatory disorders. The company is pioneering a novel approach to address these conditions, which include diseases like rheumatoid arthritis and Crohn's disease. Chronic inflammatory disorders are long-lasting conditions characterized by persistent inflammation, which can lead to severe health issues and significantly impact the quality of life.
Lipum's primary clientele includes healthcare providers, pharmaceutical companies, and patients suffering from chronic inflammatory diseases. The company operates within the global biopharmaceutical market, which is highly competitive and driven by the constant need for new and effective treatments.
The business model of Lipum revolves around research and development (R&D) of new therapeutic solutions. The company has successfully secured significant funding, including a €2.2 million grant from the European Commission's Horizon 2020 program. This financial support has been crucial in advancing their research and achieving key milestones.
Lipum generates revenue through multiple channels. Primarily, it aims to license its proprietary technology and treatments to larger pharmaceutical companies. Additionally, the company may enter into strategic partnerships and collaborations, which can provide upfront payments, milestone payments, and royalties based on the success of the developed treatments.
In summary, Lipum AB is a biotech startup dedicated to revolutionizing the treatment of chronic inflammatory disorders. By focusing on innovative R&D and leveraging strategic partnerships, the company is well-positioned to make a significant impact in the biopharmaceutical market.
Keywords: biotech, chronic inflammatory disorders, rheumatoid arthritis, Crohn's disease, healthcare, pharmaceutical, research and development, Horizon 2020, licensing, strategic partnerships.
Company overview
Lipum company information
The essential company record, classifications and operating signals in one place.
- Status
- Acquired
- Founded
- 2010
- Headquarters
- Umeå kommun, Sweden
- Employees
- 13
- Open positions
- None listed
- Dealroom signal
- 71.3
Valuation & funding
Lipum funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| ACQUISITION✓Exit | Nov 2025 | $17M | $17M | Flerie Invest | ↗ |
| GRANT✓Other financing | Dec 2024 | $0 | — | Undisclosed | ↗ |
| POST IPO EQUITY✓Other financing | Mar 2024 | $23M | — | Undisclosed | ↗ |
| GRANT✓Other financing | Dec 2023 | $36M | — | Vinnova | ↗ |
| POST IPO EQUITY✓Other financing | Sep 2022 | $4.7M | — | Flerie Invest | ↗ |
| IPO✓Exit | Jan 2021 | Undisclosed | ↗ | ||
| GRANT✓Other financing | Jul 2018 | European Innovation Council | — | ||
| GRANT✓Other financing | Oct 2016 | European Innovation Council | — | ||
| EARLY VC✓Equity / VC | 2016 | Almi Invest | — |
Financials
Revenue, earnings and profit over time
Reported history and available estimates. Estimated years are marked “E”; sparse fields are left blank rather than inferred.
Growth signals
Lipum website traffic
Latest recorded traffic for Lipum is 2.9K monthly website visits, down 25.6% over the last three months. Lipum's team declined 13.3% over the past year.
Comparisons
Lipum compared with similar companies
Dealroom’s weighted taxonomy model identifies the closest operating peers. Company identity and context stay open; selected comparison metrics preview what is available in the platform.
Talent graph
Lipum's talent
Source: Dealroom Talent Intelligence.
Investors
6 investors on Lipum's cap table
Sourced from Dealroom's funding and investor records. Investor profile links are shown where available.
Global footprint
Where Lipum has talent and traffic
team presence
In the news
Latest news about Lipum
Recent press, funding announcements, and product moves mentioning Lipum — open to read from the original sources.
Market sentiment
What the market is saying about Lipum
An AI-synthesized read of the highest-engagement posts about Lipum on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Lipum’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.